

**16 August 2016**

**SEAC/A/31/2016 FINAL**

**Final**

**Minutes of the 31<sup>st</sup> meeting of the Committee for Socio-economic Analysis**

**31 May - 9 June 2016**

## **I. Summary Record of the Proceeding**

### **1) Welcome and apologies**

Tomas Öberg, Chairman of the Committee for Socio-economic Analysis (SEAC), ECHA, welcomed the participants of the thirty-first meeting of SEAC. The Chairman informed the participants that two members have resigned. The Chairman also informed the Committee that apologies had been received from seven members.

The Chairman informed the participants that the meeting would be recorded solely for the purpose of writing the minutes and the recordings would be destroyed once no longer needed.

The list of attendees is given in Part III of the minutes.

### **2) Adoption of the Agenda**

The Chairman introduced the final draft agenda of SEAC-31. The agenda was adopted with minor modifications (under Agenda Item 7, AOB). The final agenda is attached to these minutes as Annex III. The list of all meeting documents is attached to these minutes as Annex I.

### **3) Declarations of conflicts of interest to the Agenda**

The Chairman requested members and their advisors participating in the meeting to declare any conflicts of interest to any of the specific agenda items. Three members declared potential conflicts of interest to the substance-related discussions under the Agenda Item 5.2. These members did not participate in voting under the respective Agenda Items, as stated in Article 9(2) of the SEAC Rules of Procedure.

The list with declared conflicts of interest is given in Annex II of these minutes.

### **4) Report from other ECHA bodies and activities**

#### **a) Report on SEAC-30 action points, written procedures and update other ECHA bodies**

The Chairman informed the participants that all action points of SEAC-30 had been completed or would be followed up during the on-going SEAC-31 meeting. The Chairman also informed the Committee that the final minutes of SEAC-30 had been adopted by written procedure and had been uploaded to S-CIRCABC as well as on the ECHA website. The Chairman thanked members for providing comments on the draft SEAC-30 minutes.

The Chairman then gave the floor to a SEAC member who wished that his views related to the agenda point 4b of SEAC-30 meeting (Feedback from the Commission on SEAC opinions) would be recorded in the SEAC-31 minutes. This member explained that with regard to point 4b of the previous SEAC-30 meeting, the minutes did not fully reflect his views expressed at the meeting. According to his view, the RAC and SEAC Chairmen`s quote of the Commission observer`s statement at the ENVI meeting might leave the Committee with a wrong impression that only health and environment impacts connected to the properties mentioned in the authorisation list can be included in a SEA. The Chairman invited the member to develop a note together with the Secretariat on how to address this issue.

The Chairman then explained that a report covering the developments in the ECHA MB, RAC, MSC, the Forum and BPC had been compiled and distributed to SEAC as a meeting document (SEAC/31/2016/01).

The representative of the Commission was invited to update the Committee on SEAC related developments in the REACH Committee and in CARACAL.

Furthermore, SEAC was informed about actions following the discussion in the Management Board of the European Parliament`s resolution on DEHP, and in particular the workshop on socio-economic analysis at the end of June.

## **5) Restrictions**

### **5.1) General restriction issues**

#### **a) Update on Forum restrictions projects**

The Secretariat presented the revised Working Procedure of the Forum for the elaboration of the Forum advice, the Forum Guide on Enforceability of Restriction Proposals, a methodology to recommend analytical methods, a compendium of Analytical methods and the REF-4 Project on Restrictions.

### **5.2) Restriction Annex XV dossiers**

#### **a) Opinion development**

##### **1) D4/D5 – draft final opinion**

The Chairman welcomed the dossier submitter representatives from the UK and an industry expert accompanying a stakeholder observer. He reminded the participants that this dossier, submitted by the UK in April 2015, proposes that D4 and D5 shall not be placed on the market or used in concentrations equal to or greater than 0.1% by weight of each in personal care products that are washed off in normal use conditions. The Chairman explained that the public consultation on the SEAC draft opinion ended on 16 May with nine comments received. The draft final opinion, taking into account the comments of the public consultation, was made available to SEAC on 25 May.

The rapporteurs presented the results of the public consultation and explained the revisions made in the draft final opinion. With regard to the proportionality assessment, they were interested to hear the views of SEAC members whether they agree to keep the semi-quantitative statement in the opinion referring to the WTP study. Furthermore, they were interested to hear if SEAC agrees that the information provided in the public consultation on the SEAC draft opinion was not sufficient to justify a five year compliance period over the two year compliance period previously agreed in its draft opinion. Several members supported the views of the rapporteurs on both these issues.

SEAC adopted its opinion on the dossier by consensus (with modifications introduced at SEAC-31). The rapporteurs were asked, together with the Secretariat, to make final editorial changes to the opinion and to ensure that the supporting documentation (BD and ORCOM) is in line with the adopted SEAC opinion. The Secretariat will forward the adopted opinion and its supportive documents to the Commission as well as publish them on the ECHA website. The Chairman thanked the rapporteurs for their work on this dossier.

## **b) Conformity check**

### **1. TDFAs – outcome of the conformity check and presentation of the key issues**

The Chairman welcomed the RAC rapporteurs and the dossier submitter representatives from Denmark. He informed the participants that the dossier was submitted in February 2016 (within the 60 days resubmission window after concluded not in conformity by RAC and SEAC in November 2015.) The conformity check process was launched on 4 May and the SEAC commenting round finished on 16 May (there were no comments received from SEAC members).

The dossier submitter's representative provided a brief introductory presentation on the main updates made in the dossier. The restriction proposal proposes a restriction on the use of (3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl)silanetriol and any of its mono-, di- or tri-O-(alkyl) derivatives in mixtures containing organic solvents placed on the market or used in spray products for consumers (aerosol dispensers, hand pump and trigger sprays and mixtures marketed for spray application). The restriction is targeted at mixtures with organic solvents in spray products for supply to the general public. TDFAs have been shown to cause serious acute lung injury in mice exposed to aerosolised mixtures containing TDFAs and organic solvent at certain concentration levels.

The RAC rapporteur gave a short update from RAC-37 discussions, where RAC had concluded that the dossier is in conformity. The SEAC rapporteurs presented the outcome of the conformity check and the recommendations to the dossier submitter and proposed to the Committee that the dossier can be considered in conformity from the SEAC point of view. After the short discussion, the Committee agreed that the dossier does conform to the Annex XV requirements. In addition, the rapporteurs presented the key issues identified by them in the dossier. The Chairman informed the Committee that the public consultation on this restriction proposal will be launched on 15 June 2016.

## **2. Diisobutyl phthalate (DIBP), Dibutyl phthalate (DBP), Benzyl butyl phthalate (BBP), Bis(2-ethylhexyl) phthalate (DEHP) – outcome of the conformity check and presentation of the key issues**

The Chairman welcomed the dossier submitters' representatives from ECHA and Denmark. He informed the participants that the dossier was submitted in April 2016, the conformity check process was launched in the Committees on 4 May and the SEAC commenting round finished on 16 May (there were no comments received from SEAC members).

The dossier submitters' representative (ECHA) provided a brief introductory presentation on the dossier. The dossier proposes a restriction on articles containing the four phthalates (Diisobutyl phthalate (DIBP); Dibutyl phthalate (DBP); Benzyl butyl phthalate (BBP) and Bis(2-ethylhexyl) phthalate (DEHP)) for: i) indoor use and ii) outdoor use, if in contact with human skin or mucous membranes. A previous restriction report on the four phthalates was submitted by Denmark in 2011 and RAC and SEAC adopted opinions not supporting the proposal. The four phthalates were included in Annex XIV of REACH (the Authorisation List). Applications for authorisation were received only for certain uses of DEHP and DBP. The current proposal from ECHA and Denmark builds on the previous restriction proposal and takes into account the applications for authorisation that have been submitted and granted. The new proposal presents: additional information and assessment covering the hazard, new information on exposure (especially DEMOCOPHES biomonitoring data), additional data on costs and trends in substitution, and a review of new information on benefits.

The Secretariat gave a short update from RAC-37 discussions, where RAC concluded that the dossier is in conformity. The SEAC rapporteurs presented the outcome of the conformity check and the recommendations to the dossier submitter and proposed to the Committee that the dossier can be considered in conformity from the SEAC point of view. After the short discussion, the Committee agreed that the dossier does conform to the Annex XV requirements. In addition, the rapporteurs presented the key issues identified by them in the dossier.

The Commission observer emphasised the importance of making it clear what kind of articles are included in the scope of the proposed restriction and expressed concerns with including electric and electronic equipment containing the four phthalates in the scope. He drew the Committee's attention to the Common Understanding Paper prepared by the Commission and endorsed by the Member States on the interface between REACH and Directive 2011/65/EU (RoHS). The four phthalates that are the subject of the current restriction dossier are all listed in Annex II to RoHS (restricted substances) and the simplest way to avoid duplications and/or inconsistencies is to exclude electric and electronic equipment from the scope of the proposed restriction. He mentioned that the Commission is currently preparing a letter to ECHA on this issue.

The Chairman informed the Committee that the public consultation on this restriction proposal will be launched on 15 June 2016.

### **5.3) Appointment of (co-)rapporteurs for restriction dossiers**

The Chairman informed the Committee about the new entries to the Registry of Intentions. A restriction proposal on Diisocyanates is expected to be submitted in October 2016 by Germany. The dossier proposes a restriction on diisocyanates; the placing on the market as substances on their own, as a constituent in other substances or in mixtures for industrial and professional uses.

In June, Italy is also expected to resubmit (to be confirmed) its proposal on N,N-Dimethylformamide (DMF) where the former rapporteurs will continue their work on this dossier.

In October 2016, ECHA, on request of the Commission, will also submit new dossier on lead and its compounds on the placing on the market and use of lead compounds to stabilise PVC and of the placing on the market of PVC articles stabilised with lead compounds. Depending on the outcome of the assessment, the scope of the restriction might be broad or targeted specifically to articles or article groups that are the main contributors to the risks targeted by this proposal.

The Secretariat will launch the calls for expression of interest for (co-)rapporteurships on these dossiers after the June plenary meeting.

In addition, in April 2017, ECHA, on request of the Commission, will also submit new dossier on lead and its compounds. The restriction is aimed at the use of lead shots over wetlands. The harmonisation of the conditions of use of lead in shot in wetlands is a priority at EU level, as national legislation has already been enacted by some Member States (or regions in some Member States) further to international action through the Agreement on the Conservation of African-Eurasian Migratory Waterbirds (AEWA) under the auspices of the UN Environment Programme (UNEP) to which the EU is a Party.

## **6) Authorisations**

### **6.1) General authorisation issues**

#### **a) Update on incoming/future applications**

The Secretariat informed the Committee that during the May submission window (6-20 May 2016) ECHA had received 22 new applications for authorisation on 30 uses of substances of very high concern: 15 applications for uses of chromium (VI) compounds, five for uses of 1,2-dichloroethane (EDC), one for the use of bis(methoxyethyl) ether (Diglyme) and finally one application for uses of 2,2'-dichloro-4,4'-methylenedianiline (MOCA).

#### **b) AFA: Capacity building:**

- The social cost of unemployment

The Chairman introduced a draft note on the SEAC's approach for valuing job losses in restriction proposals and applications for authorisation. The Secretariat presented the draft note and the report by the ECHA consultant. Then SEAC members discussed

several issues related to the document. They recommended to add a reference to the SEA guidance document, to consider the real period when a worker is without job, the social cost of unemployment due to the unequal distribution on the labour market. They pointed on some inconsistencies in the document and between the document and the ECHA Guidance.

The stakeholder observers asked about the status of the document and pointed out that reference values should be set via the guidance update.

The Secretariat explained that the paper assessed cost of job losses but not if there will be any job losses. The Secretariat will add references to the guidance document and was open to correct any inconsistencies highlighted by the members.

After the discussion, the Chairman informed the Committee that the Secretariat will consider the discussion and revise the draft note accordingly. The draft note will go for written consultation after SEAC-31 and for agreement at the next SEAC plenary meeting in September.

- Willingness-to-pay values for various health endpoints associated with chemicals exposure

The Chairman introduced a draft note on reference values for evaluating health impacts. The Secretariat presented the draft paper. Then SEAC members discussed several issues related to the document. SEAC would prefer to keep flexibility to the applicants, the dossier submitters and SEAC to use other values if they would be properly justified. They asked for more background information and pointed out that the list is too short. Some of the members were of the opinion that it does not include all costs and values presented are too low.

Some of the stakeholder observers questioned the status of the document and the methodology of the studies. Others were proposing references to the OECD studies and welcomed the paper as reference helping especially SMEs to prepare their applications.

The Secretariat explained that the paper is based on the study commissioned by ECHA and foreseen to establish a set of reference values.

After the discussion, the Chairman informed the Committee that the draft note will go for written consultation after SEAC-31 and for agreement at the next SEAC plenary meeting in September.

### **c) Report of the AFA task force activities**

The Secretariat presented to the Committee an activity report of the Task Force on the Workability of Applications for Authorisation (AFA TF). The Secretariat reminded that the Task Force was established in August 2014, and it consists of the representatives from the Commission, Member State Competent Authorities, and members from RAC, SEAC and the Secretariat. The Task Force assists with technical and practical aspects of applications for authorisation in selected special cases. It also assists with technical and practical aspects of general streamlining of applications for authorisation. The most recent special cases the Task Force has dealt with were substances of very high concern used in low quantities, and substances in legacy spare parts. The Task Force also dealt with substances in biologically essential nutrients. The Secretariat introduced to the Committee the objectives of the Task Force during the time period of 2016/2017. In

2016 the main focus of the Task Force has been put on the development of the practical guide, which would be comprehensive and at the same time would complement an existing guidance. In accordance with the current planning, the practical guide developed by the Task Force with the involvement of RAC and SEAC could be agreed by the end of 2016.

## **6.2) Authorisation applications**

### **a) Outcome of the conformity check and presentation of the key issues**

1. Chromium trioxide\_SNECMA
2. Chromium trioxide\_MTU
3. Chromium trioxide\_ABLOY
4. Chromium trioxide\_HOOGOSENS Court Roll Surface Technologies
5. Chromium trioxide\_TOPOCROM GmbH
6. Chromium trioxide\_FN HERSTAL S.A.
7. Chromium trioxide\_GERHARDI KUNSTOFFTECHNIK GmbH
8. Chromium trioxide; Potassium dichromate; Sodium dichromate\_SOURIAU SAS
9. Chromium trioxide\_HAPOC
10. Ammonium dichromate\_VECO BV
11. Potassium dichromate\_GENTROCHEMA BV
12. Sodium dichromate\_GENTROCHEMA BV
13. Sodium dichromate\_TOTAL RAFFINERIE MITTELDEUTSCHLAND GmbH
14. Sodium dichromate\_JACOBS DOUWEE EGBERTS DE GmbH
15. EDC\_BASF SE
16. EDC\_ELI LILLY S.A.
17. EDC\_DOW ITALIA S.R.L.
18. EDC\_LANXESS Deutschland GmbH
19. EDC\_H&R OLWERKE SCHINDLER GmbH
20. EDC\_GRUPPA LOTOS S.A.
21. EDC\_GE HEALTHCARE Bio-Sciences
22. Diglyme\_ROCHE DIAGNOSTIC GmbH
23. Diglyme\_LIFE TECHNOLOGIES A.S.
24. Diglyme\_BRACCO IMAGING S.P.A.
25. Diglyme\_MAFLOM S.P.A.
26. Diglyme\_ACTON TECHNOLOGIES Limited
27. Diglyme\_ISOCEM
28. Technical MDA\_POLYNT COMPOSITES France
29. EDC\_EURENCO

The Secretariat in cooperation with the respective SEAC rapporteurs provided general information regarding the 29 applications for authorisation as listed above. In the presentations of the cases the Secretariat outlined issues which would need further clarification by the applicants and asked the Committee for comments and further suggestions.



The Secretariat presented a list of proposals of the conformity check of the 28 applications for authorisation. With regard to the application on Chromium trioxide submitted by HAPOC, SEAC discussed in detail whether the application does conform to the requirements of the REACH Regulation.

SEAC agreed on the conformity of all 29 applications for authorisation. The Committee also discussed the key issues identified by the rapporteurs in the applications. The Secretariat will inform the applicants about the outcome of the conformity checks and will request further clarifications on the issues identified and discussed by the Committee.

## **b) Agreement on draft opinions**

### 1. Chromium trioxide 1 (5 uses) (CT\_Lanxess) – third versions of the draft opinions

The Chairman introduced a state of the application for authorisation. At the previous meeting, the rapporteurs presented and SEAC discussed the second versions of the SEAC draft opinions. The Committee agreed on the draft opinion on Use 6 by consensus. The Committee also agreed in principle on the draft opinions on Uses 1 and 2, except for the recommended review periods to be discussed further at this meeting. At the previous meeting SEAC also discussed and supported the approach taken by the rapporteurs in the draft opinions on Uses 3, 4 and 5. The SEAC members were asked to consider the agreement on the SEAC draft opinion at this plenary.

The Chairman invited the Secretariat to inform SEAC about the discussion held at RAC-37. The Secretariat briefly presented the main points of the discussion. The SEAC rapporteurs then presented the third versions of the SEAC draft opinions on the Uses 1 to 5.

The Committee discussion mainly focused on the alternatives analysed by the applicant, the non-use scenario, unemployment costs, and the calculations of the impact from the man via the environment exposure, as well as the respective cost-benefit ratios, and the length of the review periods. SEAC also took note of RAC's assessment that the default assumptions used for the local scale exposure assessment are conservative and likely to overestimate the risks. The draft opinions on the Uses 1, 3, 4 and 5 were subsequently agreed by consensus, and the draft opinion on the Use 2 was agreed by simple majority. The Chairman thanked the rapporteurs for their work on the application.

2. Sodium dichromate-Akzo Nobel (2 uses) (SD\_Akzo)
3. Sodium dichromate-Solvay (1 use) (SD\_Solvay)
4. Sodium dichromate-Arkema (1 use) (SD\_Arkema)
5. Sodium dichromate-Ercros (1 use) (SD\_Ercros)
6. Sodium dichromate-Electroquimica (1 use) (SD\_ELECTRQUIMICA)
7. Sodium dichromate-Kemira (1 use) (SD\_Kemira)
8. Sodium dichromate-Caffaro Brescia (1 use) (SD\_Caffaro)

The Chairman introduced the applications for authorisation covering seven applicants for 8 uses in total. At the previous meeting, SEAC agreed on the conformity of the

applications and discussed the key issues, as presented by the rapporteurs. The SEAC members were asked to consider the agreement on the SEAC draft opinions at this plenary.

The Chairman invited the Secretariat to inform SEAC about the discussion held at RAC-37. The Secretariat briefly presented the main points of the discussion. The SEAC rapporteurs then presented the first versions of the SEAC draft opinions. The Committee supported the rapporteurs' assessment, some questions were asked regarding alternatives analysed by the applicant and costs. The draft opinions were subsequently agreed by consensus and the Chairman thanked the rapporteurs for their work on these dossiers.

9. Chromium trioxide-Federal-Mogul Friedberg (1 use) (CT\_Friedberg)
10. Chromium trioxide-Federal-Mogul Valvetrain (1 use) (CT\_Valvetrain)
11. Chromium trioxide-Federal-Mogul Burscheid (1 use) (CT\_Burscheid)

The Chairman introduced the applications for authorisation, which are three separate applications submitted by the different companies of the Federal Mogul group. At the previous meeting, SEAC agreed on the conformity of the applications and discussed the key issues, as presented by the rapporteurs. The SEAC members were asked to consider the agreement on the SEAC draft opinions at this plenary.

The Chairman invited the Secretariat to inform SEAC about the discussion held at RAC-37. The Secretariat briefly presented the main points of the discussion. The SEAC rapporteurs then presented the first versions of the SEAC draft opinions. The SEAC members discussed feasibility and availability of alternatives, non-use scenarios submitted by the applicants, cost-benefit ratios for the individual applications and the conclusions that might be drawn from them, as well as justification for the evaluation of impact on the man via environment. The Committee supported the rapporteurs' assessments. The draft opinions were subsequently agreed by consensus and the Chairman thanked the rapporteurs for their work on these applications.

12. Chromic acid-Bosch (1 use) (CA\_Bosch)

The Chairman introduced the application for authorisation. At the previous meeting, SEAC agreed on the conformity of the application and discussed the key issues, as presented by the rapporteurs. The SEAC members were asked to consider the agreement on the SEAC draft opinion at this plenary.

The Chairman invited the Secretariat to inform SEAC about the discussion held at RAC-37. The Secretariat briefly presented the main points of the discussion. The SEAC rapporteurs then presented the first version of the SEAC draft opinion. The SEAC members discussed feasibility and availability of alternatives and the non-use scenario, involving proposed relocation outside EU. The SEAC members also evaluated the justification provided by the applicant for requesting an exceptionally long review period. The Committee supported the rapporteurs' assessment. The draft opinion was subsequently agreed by consensus and the Chairman thanked the rapporteurs for their work on the application.

13. Chromium trioxide-Circuit Foil Luxembourg (1 use) (CT\_Circuit)

The Chairman introduced the application for authorisation. At the previous meeting, SEAC agreed on the conformity of the application and discussed the key issues, as presented by the rapporteurs. The SEAC members were asked to consider the agreement on the SEAC draft opinion at this plenary.

The RAC rapporteur updated members on the deliberations at RAC-37. The SEAC rapporteurs presented the first version of the SEAC draft opinion. The Committee's discussion on the economic feasibility of alternatives mainly focused on the issue of requalification, its cost, necessity and influence to the applicant's customer decisions. SEAC discussed also the review period and the possible conditions for the review report. The Chairman concluded that the Secretariat will launch a written consultation on the updated draft opinion and it will be scheduled for agreement at the September SEAC plenary.

14. Arsenic acid-Circuit Foil Luxembourg (1 use) (AsA\_Circuit)

The Chairman introduced the application for authorisation. At the previous meeting, SEAC agreed on the conformity of the application and discussed the key issues, as presented by the rapporteurs. The SEAC members were asked to consider the agreement on the SEAC draft opinion at this plenary.

The SEAC rapporteurs presented the first version of the SEAC draft opinion. The Committee discussion mainly focused on the credibility of the substitution planning activities and the conclusion that there are no alternatives technically suitable. Some SEAC members questioned the need for a detailed analysis of the economic feasibility of the alternatives as they are not economically suitable. Then the discussion focussed on the review period and the need of setting conditions. The Chairman concluded that the Secretariat will launch a written consultation on the updated draft opinion and it will be scheduled for agreement at the September SEAC plenary.

15. Chromium trioxide and dichromium tris(chromate)-Nexter Mechanics (4 uses) (CT\_DtC\_Nexter)

The Chairman introduced the application for authorisation, which is application on the uses of chromium trioxide in the Uses 1, 2 and 3, and a combined use of both chromium trioxide and dichromium tris(chromate) in the Use 4. At the previous meeting, SEAC agreed on the conformity of the application and discussed the key issues, as presented by the rapporteurs. The SEAC members were asked to consider the agreement on the SEAC draft opinions at this plenary.

The Chairman invited the Secretariat to inform SEAC about the discussion held at RAC-37. The Secretariat briefly presented the main points of the discussion. The SEAC rapporteurs then presented the first versions of the SEAC draft opinions. The SEAC members discussed feasibility and availability of alternatives, as well as the cost-benefit analysis. The Committee also discussed "distributional impacts", i.e. impacts to the French national sovereignty, used as a factor in the socio-economic analysis by the

applicants. The Committee supported the rapporteurs' assessment. The draft opinions were subsequently agreed by consensus and the Chairman thanked the rapporteurs for their work on the application.

16. Chromium trioxide-Praxair (2 uses) (CT\_Praxair)

The Chairman introduced the application for authorisation. At the previous meeting, SEAC agreed on the conformity of the application and discussed the key issues, as presented by the rapporteurs. The SEAC members were asked to consider the agreement on the SEAC draft opinions at this plenary.

The RAC rapporteurs updated the members on the deliberations at RAC-37. The SEAC rapporteurs presented the first versions of the SEAC draft opinions. The SEAC members briefly discussed the interpretation of profit losses in case of re-location. They agreed that in those cases the (losses of) profit should rather be expressed as re-distribution costs which is also in line with the guidance. SEAC did not raise any reservations that would change the validity of the applicant's conclusion that overall benefits of the use outweigh the risk to human health or the environment. The draft opinions were subsequently agreed by consensus and the Chairman thanked the rapporteurs for their work on the application.

17. Potassium dichromate-Sofradir (2 uses) (PD\_Sofradir)

The Chairman introduced the application for authorisation. At the previous meeting, SEAC agreed on the conformity of the application and discussed the key issues, as presented by the rapporteurs. The SEAC members were asked to consider the agreement on the SEAC draft opinions at this plenary.

The RAC rapporteurs updated the members on the deliberations at RAC-37. The SEAC rapporteurs presented the first versions of the SEAC draft opinions. The SEAC members commented on need to handle investment losses consistently in the opinions on applications. The Committee supported the draft opinions as presented by the rapporteurs. The draft opinions were agreed by consensus and the Chairman thanked the rapporteurs for their work on the application.

18. Sodium dichromate-Lanxess (1 use) (SD\_Lanxess)

The Chairman introduced the application for authorisation. At the previous meeting, SEAC agreed on the conformity of the application and discussed the key issues, as presented by the rapporteurs. The SEAC members were asked to consider the agreement on the SEAC draft opinion at this plenary.

The Chairman invited the Secretariat to inform SEAC about the discussion held at RAC-37. The Secretariat briefly presented the main points of the discussion. The SEAC rapporteurs then presented the first version of the SEAC draft opinion. The Committee supported the draft opinion as proposed by the rapporteurs. The draft opinion was subsequently agreed by consensus and the Chairman thanked the rapporteurs for their work on this dossier.

19. Ammonium dichromate-Micrometal (1 use) (AD\_Micrometal)

The Chairman introduced the application for authorisation. At the previous meeting, SEAC agreed on the conformity of the application and discussed the key issues, as presented by the rapporteurs. The SEAC members were asked to consider the agreement on the SEAC draft opinion at this plenary.

The Chairman invited the Secretariat to inform SEAC about the discussion held at RAC-37. The Secretariat briefly presented the main points of the discussion. The SEAC rapporteurs then presented the first version of the SEAC draft opinion. The SEAC members discussed both technical and economic feasibility and availability of alternative technologies. The Committee supported the rapporteurs' assessment. The draft opinion was subsequently agreed by consensus and the Chairman thanked the rapporteurs for their work on the application.

20. Chromium trioxide-Cromomed (1 use) (CT\_Cromomed)

The Chairman introduced the application for authorisation. At the previous meeting, SEAC agreed on the conformity of the application and discussed the key issues, as presented by the rapporteurs. The SEAC members were asked to consider the agreement on the SEAC draft opinion at this plenary.

The Chairman invited the Secretariat to inform SEAC about the discussion held at RAC-37. The Secretariat briefly presented the main points of the discussion. The SEAC rapporteurs then presented the first version of the SEAC draft opinion. The Committee discussion mainly focused on the alternatives analysed by the applicant as well as on the benefit-risk ratio. The draft opinion was subsequently agreed by consensus and the Chairman thanked the rapporteurs for their work on this dossier.

21. Chromium trioxide-Rimex Metals (1 use) (CT\_Rimex)

The Chairman introduced the application for authorisation. At the previous meeting, SEAC agreed on the conformity of the application and discussed the key issues, as presented by the rapporteurs. The SEAC members were asked to consider the agreement on the SEAC draft opinion at this plenary.

The Chairman invited the Secretariat to inform SEAC about the discussion held at RAC-37. The Secretariat briefly presented the main points of the discussion. The SEAC rapporteurs then presented the first version of the SEAC draft opinion. The Committee supported the draft opinion as proposed by the rapporteurs (removing the condition for reporting<sup>1</sup>). The draft opinion was subsequently agreed by consensus and the Chairman thanked the rapporteurs for their work on this dossier.

---

<sup>1</sup> The issue in general will be considered in the practical guide developed by the AfA Taskforce.

## 22. EDC-BASF (1 use) (EDC\_BASF)

The Chairman introduced the application for authorisation. At the previous meeting, SEAC agreed on the conformity of the application and discussed the key issues, as presented by the rapporteurs. The SEAC members were asked to consider the agreement on the SEAC draft opinion at this plenary.

The RAC rapporteur updated members on the deliberations at RAC-37. The SEAC rapporteurs presented the first version of the SEAC draft opinion. The Committee discussion mainly focused on the review period, in consideration with the possible closure of the plant in 2018 as announced by the applicant. As noted by the Commission's observer, if the plant is closed, then it is an obligation by the applicant to inform the European Commission about this change, who in turn might withdraw or modify as appropriate the authorisation.

The Committee agreed by consensus on the draft opinion as proposed by the rapporteurs and the Chairman thanked the rapporteurs for their work on this dossier.

## 23. Diglyme-Novartis (1 use) (Diglyme\_Novartis)

The Chairman introduced the application for authorisation. At the previous meeting, SEAC agreed on the conformity of the application and discussed the key issues, as presented by the rapporteurs. The SEAC members were asked to consider the agreement on the SEAC draft opinion at this plenary.

The RAC rapporteur updated members on the deliberations at RAC-37. The SEAC rapporteurs presented the first version of the SEAC draft opinion. The Committee discussed and agreed with the conclusions of the (co-)rapporteurs that no technically and economically feasible alternative substances would be available by the sunset date. The Committee discussed the length of the review period and agreed by consensus on the draft opinion as proposed by the rapporteurs. The Chairman thanked the rapporteurs for their work on this dossier.

### **c) Orientation discussion**

1. Sodium dichromate-Brenntag (3 uses) (SD\_Brenntag)
2. Potassium dichromate-Brenntag (2 uses) (PD\_Brenntag)
3. Dichromium tris(chromate)-Henkel (2 uses) (DtC\_Henkel)
4. Strontium chromate-Akzo Nobel (2 uses) (SC\_Akzo)
5. Potassium hydroxyoctaoxodizincatedichromate-PPG (2 uses) (PH\_PPG)

The Chairman introduced the five applications for authorisation. At the previous meeting, SEAC agreed on the conformity of the applications and discussed the main key issues, as presented by the rapporteurs.

The Chairman invited the Secretariat to inform SEAC about the discussion held at RAC-37. The Secretariat briefly presented the main points of the discussion and their concerns on exposure assessment and risk management measures and operational conditions in the exposure scenarios. Following that, the SEAC rapporteurs presented

their view on the key issues, as well as their first assessment of these five applications for authorisation. The rapporteurs asked SEAC for advice how to develop the draft opinions on these applications.

SEAC members expressed their concerns on the broad scope of the uses and on the high uncertainties in the applications. The Committee discussed the robustness of the human health impact analysis, assessment of potential job losses in the non-use scenario and the geographic boundaries of the analysis. The applicants will be requested to clarify whether the alternative substances which are produced by some of the applicants, are equivalent to Cr(VI) or provide inferior corrosion protection. SEAC members supported the rapporteurs' proposal to attempt to clarify these remaining issues at the triologue discussion with the applicants which is scheduled for 21 June 2016.

The Chairman observed that the uncertainties in the excess risk estimates from local scale exposure will need to be discussed further and clarified in collaboration with RAC.

The rapporteurs will take the discussion into account in the preparation of the first version of the SEAC draft opinions. A consultation with SEAC members on the draft opinion will be held during the summer period.

### **6.3 Appointment of (co-)rapporteurs for authorisation applications (closed session)**

The pool of (co-)rapporteurs, as outlined in the amended restricted room document SEAC/31/2016/04 rev 1, was agreed by SEAC.

## **7) AOB**

### **a) Update of the workplan**

The Secretariat provided an update of the workplan for the future months.

### **b) Report from the PBT working group**

The Secretariat presented the revisions made in the framework 'Evaluation of restriction reports and applications for authorisation for PBT and vPvB substances in SEAC', taking into account the discussion of SEAC-30 in March. The Chairman invited the members to discuss the revisions made and to agree on the framework as the final report of the Working Group.

SEAC agreed with the framework (SEAC/31/2016/05) as the final report of the Working Group, subject to some editorial changes. The final report will be made available on ECHA's website. If new approaches will become available, the SEAC framework may be updated.

### **c) Outcome of 2015 stakeholder survey**

The Secretariat presented the outcome of 2015 stakeholder survey. It was agreed that the Secretariat will consider organising a short capacity building session on S-CIRCABC in the margins of SEAC-32.

### **d) Benefits of REACH and ECHA's second 5-year report on REACH and CLP**

The Secretariat provided a report on benefits of REACH and ECHA's second 5-year report on REACH and CLP. Based on its findings, REACH is working and ECHA sees no urgent need to amend it. However, some areas for improvements have been identified. Some recommendations of relevance for SEAC is that Member States and stakeholders with ECHA are invited to further clarify the role of SEA and SEAC in REACH, and to continue with their support for the work of the ECHA Committees.

### **e) Report on health costs that may be associated with endocrine disrupting chemicals**

An advisor to a member presented a report carried out by RIVM on the health costs that might be associated with endocrine disrupting (ED) chemicals. Based on the report, potential size of the problem and resulting societal costs can be substantial and include a large number of potential health effects. Furthermore, the available societal cost estimates are very uncertain and there is no uniform approach to calculate these costs. The advisor concluded, that basic information requirements in REACH provide very limited information on health effects that potentially relate to ED MoA, resulting that in practice it will be difficult to incorporate these (potentially relevant) health effects into the risk assessment and the health impact assessment. Suggestions for improvements included testing strategies, a modular approach and use of break-even analysis.

### **f) Update on AfA review report format**

The Secretariat provided a brief presentation to inform SEAC about an update on AfA review report format. The approach to be taken will be included in the practical guide that ECHA will make public by the end of 2016. In addition, first review report of AfA will be due in mid-2017.

## **8) Action points and main conclusions of SEAC-31**

A table with the action points and main conclusions is given in Part II below.



## II. Main conclusions and action points

**SEAC-31, 31 May-09 June 2016**

(Adopted at SEAC-31 meeting)

<b>Agenda point</b>	<b>Action requested after the meeting (by whom/by when)</b>
<b>Conclusions / decisions / minority opinions</b>	
<b>2. Adoption of the agenda</b>	
The agenda was adopted with minor modifications.	<b>SECR</b> to upload the adopted agenda to SEAC S-CIRCABC IG as part of the meeting minutes.
<b>3. Declarations of conflicts of interest to the Agenda</b>	
Conflicts of interest have been declared and will be taken to the minutes.	
<b>4. Report from other ECHA bodies and activities</b>	
<i>a) Report on SEAC-30 action points, written procedures and update on other ECHA bodies</i>	
SEAC was informed on the status of the action points of SEAC-30. Furthermore, SEAC took note of the report from other ECHA bodies (SEAC/31/2016/01), including the oral report from the Commission on SEAC related developments in the REACH Committee and in the CARACAL.  SEAC was also informed about actions following the European Parliament resolution on DEHP.	
<b>5. Restrictions</b>	
<b>5.1 Restriction Annex XV dossiers</b>	
a) Opinion development	
1) D4/D5 – draft final opinion	
SEAC rapporteurs presented and SEAC discussed the draft of the SEAC final opinion and the results of the public consultation on the SEAC draft opinion.  SEAC adopted its final opinion on the D4/D5 proposal by consensus (with modifications introduced at SEAC-31).	<b>Rapporteurs</b> together with <b>SECR</b> to do the final editing of the SEAC opinion and to ensure that the supporting documentation (BD and ORCOM) is in line with the adopted SEAC final opinion.  <b>SECR</b> to forward the adopted opinion and its annexes to COM and publish it on the ECHA website.
b) Conformity check	
1) TDFAs – Outcome of the conformity check and presentation of key issues	

<p>SEAC agreed that the dossier does conform to the Annex XV requirements.</p> <p>SEAC took note of the recommendations to the dossier submitter as well as of the key issues identified by the rapporteurs.</p>	<p><b>SECR</b> to compile the RAC and SEAC final outcomes of the conformity check and upload this to S-CIRCABC IG.</p> <p><b>SECR</b> to inform the dossier submitter on the outcome of the conformity check.</p>
<p>2) Diisobutyl phthalate (DIBP), Dibutyl phthalate (DBP), Benzyl butyl phthalate (BBP), Bis(2-ethylhexyl) phthalate (DEHP) – outcome of the conformity check and presentation of the key issues</p>	
<p>SEAC agreed that the dossier does conform to the Annex XV requirements.</p> <p>SEAC took note of the recommendations to the dossier submitter as well as of the key issues identified by the rapporteurs.</p>	<p><b>SECR</b> to compile the RAC and SEAC final outcomes of the conformity check and upload this to S-CIRCABC IG.</p> <p><b>SECR</b> to inform the dossier submitter on the outcome of the conformity check.</p>
<p><b>6. Authorisation</b></p>	
<p><b>6.1 General authorisation issues</b></p>	
<p>a) Update on incoming/future applications</p>	
<p>SEAC took note of the update on the incoming/future applications for authorisation.</p>	
<p>b) AfA: Capacity building:</p>	
<p>- The social cost of unemployment</p>	
<p>SEAC discussed the draft note prepared by SECR on the SEAC's approach for valuing job losses in restriction proposals and applications for authorisation (SEAC/31/2016/02).</p>	<p><b>SECR</b> to organise a written consultation on the draft note after SEAC-31.</p> <p><b>SECR</b> to amend and modify the approach, taking into account SEAC-31 discussion and the written consultation, and to table it for agreement at SEAC-32 in September 2016.</p>
<p>- Willingness-to-pay values for various health endpoints associated with chemicals exposure</p>	
<p>SEAC discussed the draft note prepared by SECR on reference values for evaluating health impacts (SEAC/31/2016/03).</p>	<p><b>SECR</b> to organise a written consultation on the draft note after SEAC-31.</p> <p><b>SECR</b> to amend the draft note, taking into account SEAC-31 discussion and the written consultation, and to table it for agreement at SEAC-32 in September 2016.</p>
<p>c) Report of the AfA task force activities</p>	

SEAC took note of the report on the AfA task force activities.	
<b>6.2 Authorisation applications</b>	
a) Outcome of the conformity check and presentation of the key issues	
<ol style="list-style-type: none"> <li>1. Chromium trioxide_SNECMA</li> <li>2. Chromium trioxide_MTU</li> <li>3. Chromium trioxide_ABLOY</li> <li>4. Chromium trioxide_HOOGOSENS Court Roll Surface Technologies</li> <li>5. Chromium trioxide_TOPOCROM GmbH</li> <li>6. Chromium trioxide_FN HERSTAL S.A.</li> <li>7. Chromium trioxide_GERHARDI KUNSTOFFTECHNIK GmbH</li> <li>8. Chromium trioxide; Potassium dichromate; Sodium dichromate_SOURIAU SAS</li> <li>9. Chromium trioxide_HAPPOC</li> <li>10. Ammonium dichromate_VECO BV</li> <li>11. Potassium dichromate_GENTROCHEMA BV</li> <li>12. Sodium dichromate_GENTROCHEMA BV</li> <li>13. Sodium dichromate_TOTAL RAFFINERIE MITTELDEUTSCHLAND GmbH</li> <li>14. Sodium dichromate_JACOBS DOUWEE EGBERTS DE GmbH</li> <li>15. EDC_BASF SE</li> <li>16. EDC_ELI LILLY S.A.</li> <li>17. EDC_DOW ITALIA S.R.L.</li> <li>18. EDC_LANXESS Deutschland GmbH</li> <li>19. EDC_H&amp;R OLWERKE SCHINDLER GmbH</li> <li>20. EDC_GRUPPA LOTOS S.A.</li> <li>21. EDC_GE HEALTHCARE Bio-Sciences</li> <li>22. Diglyme_ROCHE DIAGNOSTIC GmbH</li> <li>23. Diglyme_LIFE TECHNOLOGIES A.S.</li> <li>24. Diglyme_BRACCO IMAGING S.P.A.</li> <li>25. Diglyme_MAFLOX S.P.A.</li> <li>26. Diglyme_ACTON TECHNOLOGIES Limited</li> <li>27. Diglyme_ISOCEM</li> <li>28. Technical MDA_POLYNT COMPOSITES France</li> <li>29. EDC_EURENCO</li> </ol>	
SEAC agreed that the applications are in conformity and discussed the key issues identified in these applications.	<p><b>SECR</b> to inform the applicants about the conformity of the applications for authorisation.</p> <p><b>Rapporteurs</b> to take the discussions into account in the preparation of the first versions of the draft opinions.</p>
b) Agreement on draft opinions	
1. Chromium trioxide 1 (5 uses) (CT_Lanxess) – third version of the draft opinion	
SEAC rapporteur presented and SEAC discussed	<b>Rapporteurs</b> together with <b>SECR</b> to do the final

<p>the third versions of the SEAC draft opinions.</p> <p>SEAC agreed on the draft opinions on Uses 1, 3, 4 and 5 by consensus.</p> <p>SEAC agreed on the draft opinion on Use 2 by simple majority.</p>	<p>editing of the draft opinions.</p> <p><b>SECR</b> to send the draft opinions to the applicant for commenting.</p>
<p>2. Sodium dichromate-Akzo Nobel (2 uses) (SD_Akzo)</p>	
<p>SEAC rapporteurs presented and SEAC discussed the SEAC draft opinions.</p> <p>SEAC agreed on the draft opinions on Uses 1 and 2 by consensus.</p>	<p><b>Rapporteurs</b> together with <b>SECR</b> to do the final editing of the draft opinions.</p> <p><b>SECR</b> to send the draft opinions to the applicant for commenting.</p>
<p>3. Sodium dichromate-Solvay (1 use) (SD_Solvay)</p>	
<p>SEAC rapporteurs presented and SEAC discussed the SEAC draft opinion.</p> <p>SEAC agreed on the draft opinion by consensus.</p>	<p><b>Rapporteurs</b> together with <b>SECR</b> to do the final editing of the draft opinion.</p> <p><b>SECR</b> to send the draft opinion to the applicant for commenting.</p>
<p>4. Sodium dichromate-Arkema (1 use) (SD_Arkema)</p>	
<p>SEAC rapporteurs presented and SEAC discussed the SEAC draft opinion.</p> <p>SEAC agreed on the draft opinion by consensus.</p>	<p><b>Rapporteurs</b> together with <b>SECR</b> to do the final editing of the draft opinion.</p> <p><b>SECR</b> to send the draft opinion to the applicant for commenting.</p>
<p>5. Sodium dichromate-Ercros (1 use) (SD_Ercros)</p>	
<p>SEAC rapporteurs presented and SEAC discussed the SEAC draft opinion.</p> <p>SEAC agreed on the draft opinion by consensus.</p>	<p><b>Rapporteurs</b> together with <b>SECR</b> to do the final editing of the draft opinion.</p> <p><b>SECR</b> to send the draft opinion to the applicant for commenting.</p>
<p>6. Sodium dichromate-Electroquimica (1 use) (SD_ELECTRQUIMICA)</p>	
<p>SEAC rapporteurs presented and SEAC discussed the SEAC draft opinion.</p> <p>SEAC agreed on the draft opinion by consensus.</p>	<p><b>Rapporteurs</b> together with <b>SECR</b> to do the final editing of the draft opinion.</p> <p><b>SECR</b> to send the draft opinion to the applicant for commenting.</p>
<p>7. Sodium dichromate-Kemira (1 use) (SD_Kemira)</p>	
<p>SEAC rapporteurs presented and SEAC discussed the SEAC draft opinion.</p> <p>SEAC agreed on the draft opinion by consensus.</p>	<p><b>Rapporteurs</b> together with <b>SECR</b> to do the final editing of the draft opinion.</p> <p><b>SECR</b> to send the draft opinion to the applicant for commenting.</p>

8. Sodium dichromate-Caffaro Brescia (1 use) (SD_Caffaro)	
SEAC rapporteurs presented and SEAC discussed the SEAC draft opinion.  SEAC agreed on the draft opinion by consensus.	<b>Rapporteurs</b> together with <b>SECR</b> to do the final editing of the draft opinion.  <b>SECR</b> to send the draft opinion to the applicant for commenting.
9. Chromium trioxide-Federal-Mogul Friedberg (1 use) (CT_Friedberg)	
SEAC rapporteurs presented and SEAC discussed the SEAC draft opinion.  SEAC agreed on the draft opinion by consensus.	<b>Rapporteurs</b> together with <b>SECR</b> to do the final editing of the draft opinion.  <b>SECR</b> to send the draft opinion to the applicant for commenting.
10. Chromium trioxide-Federal-Mogul Valvetrain (1 use) (CT_Valvetrain)	
SEAC rapporteurs presented and SEAC discussed the SEAC draft opinion.  SEAC agreed on the draft opinion by consensus.	<b>Rapporteurs</b> together with <b>SECR</b> to do the final editing of the draft opinion.  <b>SECR</b> to send the draft opinion to the applicant for commenting.
11. Chromium trioxide-Federal-Mogul Burscheid (1 use) (CT_Burscheid)	
SEAC rapporteurs presented and SEAC discussed the SEAC draft opinion.  SEAC agreed on the draft opinion by consensus.	<b>Rapporteurs</b> together with <b>SECR</b> to do the final editing of the draft opinion.  <b>SECR</b> to send the draft opinion to the applicant for commenting.
12. Chromic acid-Bosch (1 use) (CA_Bosch)	
SEAC rapporteurs presented and SEAC discussed the SEAC draft opinion.  SEAC agreed on the draft opinion by consensus.	<b>Rapporteurs</b> together with <b>SECR</b> to do the final editing of the draft opinion.  <b>SECR</b> to send the draft opinion to the applicant for commenting.
13. Chromium trioxide-Circuit Foil Luxembourg (1 use) (CT_Circuit)	
SEAC rapporteurs presented and SEAC discussed the SEAC draft opinion.	<b>Rapporteurs</b> together with <b>SECR</b> to take the discussions into account in the revised draft opinion.  <b>SECR</b> to organise a written consultation on the revised draft opinion in summer 2016.  <b>SECR</b> to table the draft opinion for agreement in SEAC-32.
14. Arsenic acid-Circuit Foil Luxembourg (1 use) (AsA_Circuit)	
SEAC rapporteurs presented and SEAC discussed the SEAC draft opinion.	<b>Rapporteurs</b> together with <b>SECR</b> to take the discussions into account in the revised draft opinion.  <b>SECR</b> to organise a written consultation on the

	<p>revised draft opinion in summer 2016.</p> <p><b>SECR</b> to table the draft opinion for agreement in SEAC-32.</p>
<p>15. Chromium trioxide and dichromium tris(chromate)-Nexter Mechanics (4 uses) (CT_DtC_Nexter)</p>	
<p>SEAC rapporteurs presented and SEAC discussed the SEAC draft opinions.</p> <p>SEAC agreed on the draft opinions for Uses 1 to 4 by consensus.</p>	<p><b>Rapporteurs</b> together with <b>SECR</b> to do the final editing of the draft opinions.</p> <p><b>SECR</b> to send the draft opinions to the applicants for commenting.</p>
<p>16. Chromium trioxide-Praxair (2 uses) (CT_Praxair)</p>	
<p>SEAC rapporteurs presented and SEAC discussed the SEAC draft opinions.</p> <p>SEAC agreed on the draft opinions for Uses 1 and 2 by consensus.</p>	<p><b>Rapporteurs</b> together with <b>SECR</b> to do the final editing of the draft opinions.</p> <p><b>SECR</b> to send the draft opinions to the applicant for commenting.</p>
<p>17. Potassium dichromate-Sofradir (2 uses) (PD_Sofradir)</p>	
<p>SEAC rapporteurs presented and SEAC discussed the SEAC draft opinions.</p> <p>SEAC agreed on the draft opinions on Uses 1 and 2 by consensus.</p>	<p><b>Rapporteurs</b> together with <b>SECR</b> to do the final editing of the draft opinions.</p> <p><b>SECR</b> to send the draft opinions to the applicant for commenting.</p>
<p>18. Sodium dichromate-Lanxess (1 use) (SD_Lanxess)</p>	
<p>SEAC rapporteurs presented and SEAC discussed the SEAC draft opinion.</p> <p>SEAC agreed on the draft opinion by consensus.</p>	<p><b>Rapporteurs</b> together with <b>SECR</b> to do the final editing of the draft opinion.</p> <p><b>SECR</b> to send the draft opinion to the applicant for commenting.</p>
<p>19. Ammonium dichromate-Micrometal (1 use) (AD_Micrometal)</p>	
<p>SEAC rapporteurs presented and SEAC discussed the SEAC draft opinion.</p> <p>SEAC agreed on the draft opinion by consensus.</p>	<p><b>Rapporteurs</b> together with <b>SECR</b> to do the final editing of the draft opinion.</p> <p><b>SECR</b> to send the draft opinion to the applicant for commenting.</p>
<p>20. Chromium trioxide-Cromomed (1 use) (CT_Cromomed)</p>	
<p>SEAC rapporteurs presented and SEAC discussed the SEAC draft opinion.</p> <p>SEAC agreed on the draft opinion by consensus.</p>	<p><b>Rapporteurs</b> together with <b>SECR</b> to do the final editing of the SEAC draft opinion.</p> <p><b>SECR</b> to send the draft opinion to the applicant for commenting.</p>

21. Chromium trioxide-Rimex Metals (1 use) (CT_Rimex)	
SEAC rapporteurs presented and SEAC discussed the SEAC draft opinion.  SEAC agreed on the draft opinion by consensus (removing the condition for reporting).	<b>Rapporteurs</b> together with <b>SECR</b> to do the final editing of the SEAC draft opinion.  <b>SECR</b> to send the draft opinion to the applicant for commenting.
22. EDC-BASF (1 use) (EDC_BASF)	
SEAC rapporteurs presented and SEAC discussed the SEAC draft opinion.  SEAC agreed on the draft opinion by consensus.	<b>Rapporteurs</b> together with <b>SECR</b> to do the final editing of the SEAC draft opinion.  <b>SECR</b> to send the draft opinion to the applicant for commenting.
23. Diglyme-Novartis (1 use) (Diglyme_Novartis)	
SEAC rapporteurs presented and SEAC discussed the SEAC draft opinion.  SEAC agreed on the draft opinion by consensus.	<b>Rapporteurs</b> together with <b>SECR</b> to do the final editing of the SEAC draft opinion.  <b>SECR</b> to send the draft opinion to the applicant for commenting.
1. Orientation discussion	
<ol style="list-style-type: none"> <li>1. Sodium dichromate-Brenntag (3 uses) (SD_Brenntag)</li> <li>2. Potassium dichromate-Brenntag (2 uses) (PD_Brenntag)</li> <li>3. Dichromium tris(chromate)-Henkel (2 uses) (DtC_Henkel)</li> <li>4. Strontium chromate-Akzo Nobel (2 uses) (SC_Akzo)</li> <li>5. Potassium hydroxyoctaoxidizincatedichromate-PPG (2 uses) (PH_PPG)</li> </ol>	
SEAC rapporteurs presented and SEAC discussed the rapporteurs' first assessment on these applications.	<b>Rapporteurs</b> to prepare the SEAC draft opinions for a SEAC consultation.  <b>SECR</b> to launch a SEAC consultation during the summer.  <b>Rapporteurs</b> to prepare the SEAC draft opinions for discussion at SEAC-32.
<b>6.3 Appointment of (co-)rapporteurs for authorisation applications (closed session)</b>	
SEAC agreed on the updated pool of (co-) rapporteurs for applications for authorisation (considered as agreement on appointment in line with SEAC/31/2016/04 rev1 RESTRICTED room document).	<b>SEAC members</b> to volunteer to the pool of (co-) rapporteurs for applications for authorisation.  <b>SECR</b> to upload the updated document to confidential folder on S-CIRCABC IG.

<b>7. AOB</b>	
b) Report from the PBT working group	
<p>SECR presented the revised framework 'Evaluation of restriction reports and applications for authorisation for PBT and vPvB substances in SEAC (SEAC/31/2016/05).</p> <p>SEAC agreed with the framework as the final report of the Working Group.</p>	<p><b>SECR</b> to publish the framework on the ECHA website.</p>
c) Outcome of 2015 stakeholder survey	
<p>SEAC took note of the outcome of 2015 stakeholder survey.</p>	<p><b>SECR</b> to consider organising a short capacity building session on S-CIRCABC in the margins of SEAC-32.</p>
<b>8. Action points and main conclusions of SEAC-31</b>	
<p>SEAC adopted the action points and main conclusions of SEAC-31.</p>	<p><b>SECR</b> to upload the action points and main conclusions to S-CIRCABC IG.</p>



### III. List of Attendees

#### SEAC-31

<b>SEAC members</b>
ALEXANDRE Joao
ALEXANDROPOULOU Ioanna
BERGS Ivars
BRIGNON Jean-Marc
CASTELLI Stefano
COGEN Simon
CSERGŐ Robert (co-opted)
DOUGHERTY Gary
DRAKE Lars (co-opted)
FANKHAUSER Simone
FOCK Lars
FURLAN Janez
GEORGIOU Stavros
GRANDI Silvia (via WebEx)
HENNIG Philipp (co-opted)
JONES Derrick (co-opted)
KAJIĆ Silva
KIISKI Johanna
KNOFLACH Georg
KRAJNC Karmen
LOČS Jānis
LUIT Richard
LUTTIKHUIZEN Cees
LÜDEKE Andreas
MEXA Alexandra
NARROS SIERRA Adolfo
NICOLAIDES Leandros
NORING Maria
OLTEANU Maria
RYDLEWSKA-LISZKOWSKA Izabela
SCHUCHTAR Endre
SLETTEN Thea Marcelia
SMILGIUS Tomas
STOYANOVA-LAZAROVA Elina
THORS Åsa
THIELE Karen
<b>Commission observers</b>
BENGYUZOV Manol (DG GROW)
PROKE Pavel (via WebEx)

<b>Advisors, invited experts, observers &amp; dossier submitters (DS)</b>
DELCOURT Benjamin (invited expert, SEAC nominee)
KLAUS Urban (invited expert, SEAC nominee)
DOMINIAC Dorota (advisor to I. Rydlewska-L.)
JONGENEEL Rob (advisor to R. Luit)
MARTINUSSEN SNEVE Marie (advisor to T.M. Sletten)
BOHLEN Elmar
SERGIO Ramos (advisor to Adolfo, via WebEx)
VERHOEVEN Julia (advisor to L. Cees via WebEx)
<b>RAC (co-)rapporteurs</b>
SCHULTE Agnes
VARNAI Veda
BARANSKI Boguslaw
STASKO Jolanta
MULLOOLY Yvonne
NEUMANN Michael
PRONK Marja
SCHLUTER Urs
JOAO Carvalho
UŽOMECKAS Žilvinas
DUNAUŠKIENE Lina
MOELLER Ruth
SOGORB Miguel A
KADIKIS Normunds
SANTONEN Tiina
<b>Stakeholder observers &amp; accompanying experts</b>
BUONSANTE Vito (ClientEarth)
JANOSI Amaya (CEFIC)
HAIDER Sonja (ChemSec)
WAETERSCHOOT Hugo (EUROMETAUX)
MUSU Tony (ETUC)
LEMOINE Sylvie (DOW CEFIC)
HOLLAND Michael (EAERE)
VANDER STRAETEN Michel (EUROMETAUX)
<b>ECHA staff</b>
BERGES Markus
BLAINEY Mark
DVORAKOVA Dana
JACQUEMIN Katline
KANELLOPOULOU Athanasia
KIVELÄ Kalle
KOSK-BIENKO Joanna

KOULOUMPOS Vasileios
LIINA Risto
LOUKOU Christina
LOGTMEIJER Christiaan
LUDBORZS Arnis
MARQUEZ-CAMACHO Mercedes
MERKOURAKIS Spyridon
MOTTET Denis
NICOT Thierry
ORISPÄÄ Katja
ÖBERG Tomas
PELTOLA Jukka
PILLET Monique
HOLLINS Steve
HENRICHSON Sanna
REGIL Pablo
RHEINBERGER Christoph
ROGGEMAN Maarten
SADAM Diana
AJAO Peter
SIHVONEN Kirsi
SIMPSON Peter
SOSNOWSKI Piotr
STOYANOVA Evgenia
VAINIO Matti

#### **IV. List of Annexes**

- ANNEX I. List of documents submitted to the members of the Committee for Socio-economic Analysis
- ANNEX II. Declared conflicts of interest
- ANNEX III. Final Draft Agenda

**ANNEX I****Documents submitted to the members of the Committee for Socio-economic Analysis**

<b>Document</b>	<b>Number</b>
Final Draft Agenda	<i>SEAC/A/31/2016</i>
Report on SEAC-30 action points, written procedures and update on other ECHA bodies	<i>SEAC/31/2016/01</i>
AfA: Capacity Building The social cost of unemployment	<i>SEAC/31/2016/02</i>
AfA: Capacity Building Willingness-to-pay values for various health endpoints associated with chemicals exposure	<i>SEAC/31/2016/03</i>
Appointment of (co-)rapporteurs for authorisation applications (closed session)	<i>SEAC/31/2016/04</i>
Report from the PBT working group	<i>SEAC/31/2016/05</i>

**ANNEX II****DECLARATIONS OF CONFLICTS OF INTEREST TO THE RESPECTIVE AGENDA ITEMS**

The following participants declared conflicts of interests with the agenda items below (according to Article 9(2) of the SEAC Rules of Procedure):

<b><u>Name of participant</u></b>	<b><u>Agenda item</u></b>	<b><u>Interest declared</u></b>
FOCK Lars	5.2b-2 phthalates	Participation in the preparation of the restriction dossier
FOCK Lars	5.2b-1 TDFAs	Working for the MSCA submitting the restriction dossier
DOUGHERTY Gary	5.2a-1 D4/D5	Participation in the preparation of the restriction dossier
GEORGIOU Stavros	5.2a-1 D4/D5	Participation in the preparation of the restriction dossier

31 May 2016  
SEAC/A/31/2016

**Final Draft Agenda**  
**31<sup>st</sup> meeting of the Committee for Socio-economic Analysis**

**31 May - 9 June 2016**

**ECHA Conference Centre (Annankatu 18, Helsinki)**

**31 May starts at 10.00**  
**3 June breaks at 13.00**  
**7 June resumes at 14.00**  
**9 June ends at 14.00**

**Item 1 – Welcome and Apologies**

**Item 2 – Adoption of the Agenda**

***SEAC/A/31/2016***  
***For adoption***

**Item 3 – Declarations of conflicts of interest to the Agenda**

**Item 4 – Report from other ECHA bodies and activities**

- a) Report on SEAC-30 action points, written procedures and update on other ECHA bodies

***SEAC/31/2016/01***  
***For information***

**Item 5 – Restrictions**

**5.1 General restriction issues**

- a) Update on Forum restrictions projects

***For information***

## 5.2 Restriction Annex XV dossiers

### a) Opinion development

- 1) D4/D5 – draft final opinion

***For adoption***

### b) Conformity check

- 1) TDFAs – outcome of the conformity check and presentation of the key issues
- 2) Diisobutyl phthalate (DIBP), Dibutyl phthalate (DBP), Benzyl butyl phthalate (BBP), Bis(2-ethylhexyl) phthalate (DEHP) – outcome of the conformity check and presentation of the key issues

***For agreement***

## 5.3 Appointment of (co-)rapporteurs for restriction dossiers

***For information***

## Item 6 – Authorisation

### 6.1 General authorisation issues

#### a) Update on incoming/future applications

***For information***

#### b) AfA: Capacity building:

- The social cost of unemployment

***SEAC/31/2016/02***

***For discussion***

- Willingness-to-pay values for various health endpoints associated with chemicals exposure

***SEAC/31/2016/03***

***For discussion and agreement***

#### c) Report of the AfA task force activities

***For information***

### 6.2 Authorisation applications

#### c) Outcome of the conformity check and presentation of the key issues

1. Chromium trioxide\_SNECMA
2. Chromium trioxide\_MTU

3. Chromium trioxide\_ABLOY
4. Chromium trioxide\_HOOGOSENS Court Roll Surface Technologies
5. Chromium trioxide\_TOPOCROM GmbH
6. Chromium trioxide\_FN HERSTAL S.A.
7. Chromium trioxide\_GERARDHI KUNSTOFFTECHNIK GmbH
8. Chromium trioxide; Potassium dichromate; Sodium dichromate\_SOURIAU SAS
9. Chromium trioxide\_HAPPOC
10. Ammonium dichromate\_VECO BV
11. Potassium dichromate\_GENTROCHEMA BV
12. Sodium dichromate\_GENTROCHEMA BV
13. Sodium dichromate\_TOTAL RAFFINERIE MITTELDEUTSCHLAND GmbH
14. Sodium dichromate\_JACOBS DOUWEE EGBERTS DE GmbH
15. EDC\_BASF SE
16. EDC\_ELI LILLY S.A.
17. EDC\_DOW ITALIA S.R.L.
18. EDC\_LANXESS Deutschland GmbH
19. EDC\_H&R OLWERKE SCHINDLER GmbH
20. EDC\_GRUPPA LOTOS S.A.
21. EDC\_GE HEALTHCARE Bio-Sciences
22. Diglyme\_ROCHE DIAGNOSTIC GmbH
23. Diglyme\_LIFE TECHNOLOGIES A.S.
24. Diglyme\_BRACCO IMAGING S.P.A.
25. Diglyme\_MAFLOX S.P.A.
26. Diglyme\_ACTON TECHNOLOGIES Limited
27. Diglyme\_ISOCEM
28. Technical MDA\_POLYNT COMPOSITES France
29. EDC\_EURENCO

***For discussion and agreement***

d) Agreement on draft opinions

1. Chromium trioxide 1 (5 uses) (CT\_Lanxess) – third version of the draft opinion
2. Sodium dichromate-Akzo Nobel (2 uses) (SD\_Akzo)
3. Sodium dichromate-Solvay (1 use) (SD\_Solvay)
4. Sodium dichromate-Arkema (1 use) (SD\_Arkema)
5. Sodium dichromate-Ercros (1 use) (SD\_Ercros)
6. Sodium dichromate-Electroquimica (1 use) (SD\_ELECTROQUIMICA)
7. Sodium dichromate-Kemira (1 use) (SD\_Kemira)
8. Sodium dichromate-Caffaro Brescia (1 use) (SD\_Caffaro)
9. Chromium trioxide-Federal-Mogul Friedberg (1 use) (CT\_Friedberg)
10. Chromium trioxide-Federal-Mogul Valvetrain (1 use) (CT\_Valvetrain)
11. Chromium trioxide-Federal-Mogul Burscheid (1 use) (CT\_Burscheid)
12. Chromic acid-Bosch (1 use) (CA\_Bosch)



13. Chromium trioxide-Circuit Foil Luxembourg (1 use) (CT\_Circuit)
14. Arsenic acid-Circuit Foil Luxembourg (1 use) (AsA\_Circuit)
15. Chromium trioxide and dichromium tris(chromate)-Nexter Mechanics (4 uses) (CT\_DtC\_Nexter)
16. Chromium trioxide-Praxair (2 uses) (CT\_Praxair)
17. Potassium dichromate-Sofradir (2 uses) (PD\_Sofradir)
18. Sodium dichromate-Lanxess (1 use) (SD\_Lanxess)
19. Ammonium dichromate-Micrometal (1 use) (AD\_Micrometal)
20. Chromium trioxide-Cromomed (1 use) (CT\_Cromomed)
21. Chromium trioxide-Rimex Metals (1 use) (CT\_Rimex)
22. EDC-BASF (1 use) (EDC\_BASF)
23. Diglyme-Novartis (1 use) (Diglyme\_Novartis)

***For discussion and agreement***

e) Orientation discussion

1. Sodium dichromate-Brenntag (3 uses) (SD\_Brenntag)
2. Potassium dichromate-Brenntag (2 uses) (PD\_Brenntag)
3. Dichromium tris(chromate)-Henkel (2 uses) (DtC\_Henkel)
4. Strontium chromate-Akzo Nobel (2 uses) (SC\_Akzo)
5. Potassium hydroxyoctaoxodizincatedichromate-PPG (2 uses) (PH\_PPG)

***For discussion***

**6.3 Appointment of (co-)rapporteurs for authorisation applications (closed session)**

***SEAC/31/2016/04***

***(restricted room document)***

***For agreement***

**Item 7 – AOB**

a) Update of the work plan

***For information***

b) Report from the PBT working group

***SEAC/31/2016/05***

***For agreement***

c) Outcome of 2015 stakeholder survey

***For information***

d) Benefits of REACH and ECHA's second 5-year report on REACH and CLP

***For information***

- e) Report on health costs that may be associated with endocrine disrupting chemicals

***For information***

- f) Update on AfA review report format

***For information***

**Item 8 – Action points and main conclusions of SEAC-31**

Table with Conclusions and Action points from SEAC-31

***For adoption***